Joshua Brody, MD
Enriched profileProfessor of Medicine (Hematology and Medical Oncology), Immunology and Immunotherapy, and Oncological Sciences; Director, Lymphoma Immunotherapy Program, The Tisch Cancer Institute at Mount Sinai · Icahn School of Medicine at Mount Sinai
Joshua Brody is Professor of Medicine (Hematology and Medical Oncology), Immunology and Immunotherapy, and Oncological Sciences; Director, Lymphoma Immunotherapy Program, The Tisch Cancer Institute at Mount Sinai at Icahn School of Medicine at Mount Sinai. OpenAlex indexes 347 publications with 10,269 citations (h-index 45); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Joshua Brody, M.D., is Professor of Medicine (Hematology and Medical Oncology), Immunology and Immunotherapy, and Oncological Sciences at Icahn School of Medicine at Mount Sinai. The public record shows 347 publications with 10,269 citations (h-index 45), centered on CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Immunotherapy and Immune Responses. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 28 companies, 2 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Science (New York, N.Y.)
- Top research focus: CAR-T cell therapy research
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 102.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
Sponsor: Joshua Brody
- Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Sponsor: Beth Israel Deaconess Medical Center
- Epcoritamab and Rituximab for First-line Follicular Lymphoma
Sponsor: Reid Merryman, MD
Industry payments
Updated 18 Oct 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202517 payments$37,942openpaymentsdata.cms.gov ↗
- ADC THERAPEUTICS AMERICA, INC.Program year202521 payments$30,384openpaymentsdata.cms.gov ↗
- Genmab U.S., Inc.Program year20251 payment$25,000openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
56%Corticosteroid56%Dexamethasone100%Part D<11 patientsMetabolism & gastrointestinal
44%Corticosteroid44%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
2 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Icahn School of Medicine at Mount Sinai
FY2026$351,924R37CA246239 - Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Icahn School of Medicine at Mount Sinai
FY2025$351,924R37CA246239 - Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Icahn School of Medicine at Mount Sinai
FY2024$368,346R37CA246239
Congress activity
Updated 18 Oct 2026
67 congress contributions (2008–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract LB243: Secreted PTEN-long downregulates PI3K signaling and PD-L1 and promotes anti-tumor antigen-presenting cell functions to cause regressions of mouse tumors
AACR Annual Meeting
AACR2025Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Dendritic cells control tertiary lymphoid structure development and maintenance in cancer.
Science (New York, N.Y.)
Article2026 - mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.
Nature biotechnology
Article2026 - Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Cancer vaccines: the next immunotherapy frontierArticle850 citations2022
- 03
- 04In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II StudyArticle487 citations2010
- 05Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccinationArticle438 citations2019
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/joshua-brody-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/joshua-brody-md-a1a0412
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Joshua-Brody
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/JoshuaBrodyMD
Mentions by others
where others cite or feature them- Other
lymphoma.org/joshua-brody-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗ - Other
profiles.mountsinai.org/joshua-brody
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.mountsinai.org ↗ - Other
scholars.mssm.edu/en/persons/joshua-brody
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗ - Other
immunologypodcast.com/ep-52-lymphoma-immunotherapy-featuring-dr-joshua-brody
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →immunologypodcast.com ↗ - Other
mountsinai.org/about/newsroom/2018/hodgkin-lymphoma-research-updates-from-dr-joshua-brody
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mountsinai.org ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- M.D.
State University of New York at Stony Brook School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lymphoma.org ↗ - Board Certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Member
Society for the Immunotherapy of Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗ - Member
American Society of Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗ - Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗ - Member
Alliance for Clinical Trials in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗
- ASCO Bradley Stuart Beller Foundation Fellowship Merit Award for best abstract
2008 ASCO Annual Meeting
2008provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mountsinai.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mountsinai.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- Department of Immunology and Immunotherapy
Icahn School of Medicine at Mount Sinai
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.mountsinai.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mountsinai.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mountsinai.org ↗
- The Immunology Podcast
Episode 52: "Lymphoma Immunotherapy" featuring Dr. Joshua Brody
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →immunologypodcast.com ↗ - Q&A with Dr. Joshua Brody about a Promising New Cancer Vaccine
Damon Runyon Cancer Research Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →damonrunyon.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Gregg Stone, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Donna Mancini, MD
Icahn School of Medicine at Mount Sinai
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center